All In Biotech

Drug Trial Radar · NCT05680415

Clinical Trial of Mica

Phase IV Clinical Trial of the Safety, Efficacy, and Immunogenicity of Mycobacterium Vaccae for Injection (Mica) in People Over 15 Years of Age With Latent Mycobacterium Tuberculosis Infection

Last checked: Nov 20, 2026Latest source record: Jun 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 6,800 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

6,800

Planned (sponsor's estimate)

Start

Apr 19, 2023

Primary completion

Sep 30, 2026

Study completion Aug 31, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 15 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study used a randomized, open, blank control design. A total of 6800 patients over 15 years old with latent mycobacterium tuberculosis infection who met the inclusion criteria but did not meet the exclusion criteria were randomly assigned to the experimental group and the blank control group in a 1:1 ratio, with 3400 patients in each group. The experimental group was alternately injected with 1 dose of microcard every two weeks (0-2-4-6-8-10 weeks) in the left and right hip muscle deep, with a total of 6 doses. The blank control group was not injected with drugs.

Conditions

  • Latent Tuberculosis Infection

Interventions

  • Mycobacterium Vaccae for InjectionBiological

    The experimental group was alternately injected with 1 dose of microcard every two weeks (0-2-4-6-8-10 weeks) in the left and right hip muscle deep, and a total of 6 doses were injected.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. End point of efficacyTime frame: through study completion, an average of 2 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Liujiang district Prevention and Control center

    Liuzhou, Guangxi, China

  • Liuzhou Center for Disease Control and Prevention

    Liuzhou, Guangxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.